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Aims: To determine the global extent of hypoglycaemia experienced by patients with diabetes using insulin, as there is a lack of data on the prevalence
of hypoglycaemia in developed and developing countries.
Methods: This non-interventional, multicentre, 6-month retrospective and 4-week prospective study using self-assessment questionnaire and patient
diaries included 27 585 patients, aged ≥18 years, with type 1 diabetes (T1D; n= 8022) or type 2 diabetes (T2D; n= 19 563) treated with insulin for
>12months, at 2004 sites in 24 countries worldwide. The primary endpoint was the proportion of patients experiencing at least one hypoglycaemic
event during the observational period.
Results: During the prospective period, 83.0% of patients with T1D and 46.5% of patients with T2D reported hypoglycaemia. Rates of any, nocturnal
and severe hypoglycaemia were 73.3 [95% confidence interval (CI) 72.6–74.0], 11.3 (95% CI 11.0–11.6) and 4.9 (95% CI 4.7–5.1) events/patient-year
for T1D and 19.3 (95% CI 19.1–19.6), 3.7 (95% CI 3.6–3.8) and 2.5 events/patient-year (95% CI 2.4–2.5) for T2D, respectively. The highest rates of any
hypoglycaemia were observed in Latin America for T1D and Russia for T2D. Glycated haemoglobin level was not a significant predictor of hypoglycaemia.
Conclusions: We report hypoglycaemia rates in a global population, including those in countries without previous data. Overall hypoglycaemia rates
were high, with large variations between geographical regions. Further investigation into these differences may help to optimize therapy and reduce the
risk of hypoglycaemia.
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Introduction
Insulin therapy is essential for the treatment of type 1 dia-
betes (T1D), and is often required for people with type 2
diabetes (T2D). Hypoglycaemia remains a limiting factor in
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achieving good glycaemic control [1] and recent diabetes treat-
ment guidelines highlight the need for personalized glycated
haemoglobin (HbA1c) targets to balance reductions in hyper-
glycaemia with the potential risks of hypoglycaemia [2,3].
Previous studies in hypoglycaemia have been focused on
the safety and efficacy of particular drugs [4–7]. Data regard-
ing hypoglycaemia rates obtained from randomized controlled
trials, as opposed to observational studies, must be inter-
preted with caution as these often exclude older patients, and
those with recurrent hypoglycaemia, very poor glycaemic con-
trol (HbA1c >10%), or concomitant medical conditions, even
though these variables are often seen in the clinic. In addition,
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such studies are conducted under controlled conditions, with
regular contact and follow-up between patients and trial physi-
cians, and are often of a treat-to-target design to meet reg-
ulatory requirements [8]. Both this selection of patients and
trial design are likely to influence the observed rate of hypo-
glycaemia.
Observational studies and surveys conducted thus far
have reported somewhat higher non-severe hypoglycaemia
frequency ranges of 3.5–7.2 events/month for T1D [1,9–11]
and 0.8–4.0 events/month for T2D [1,9–13]; however, these
studies were primarily retrospective or cross-sectional studies
(leading to potential recall bias), conducted online (restricting
participation to those who have access to and ability to use
the internet, which is a potential source of selection bias,
particularly for older patients), and have thus far been limited
to North America and Europe.
Beyond hypoglycaemia rates, it is also important to examine
factors associated with hypoglycaemia to identify higher-risk
patients and to tailor treatment appropriately, particularly
with regard to setting realistic targets for glycaemic control.
Large-scale studies of hypoglycaemia rates in clinical practice
are therefore required to determine any factors associated with
hypoglycaemia, and to ascertain the real-life magnitude and
impact of hypoglycaemia rates, particularly outside Europe
and North America.
The aim of the present study, the HAT study, was to examine
the impact of hypoglycaemia in an insulin-using global patient
population in an epidemiological observational study covering
a 6-month retrospective and a 4-week prospective time period.
Research Design and Methods
Study Design
This study was a non-interventional, multicentre, 6-month
retrospective and 4-week prospective study of hypoglycaemic
events across 2004 sites in 24 countries in six regions (Eastern
Europe: Bulgaria, Croatia, Czech Republic, Hungary, Poland,
Romania, Russian Federation, Serbia, Slovakia and Slovenia;
Latin America: Argentina and Mexico; Middle East: Israel,
Lebanon and Saudi Arabia; Northern Europe/Canada: Austria,
Canada, Denmark, Finland, Germany, the Netherlands and
Sweden; Russia: Russian Federation; Southeast (SE) Asia: India
andMalaysia) using self-assessment questionnaires (SAQs) and
patient diaries (for 28 days). The site selection was a conve-
nience sample. The study was rolled out over a period of
1 year from 2012 to 2013 in a staggered fashion (start times
varied by country). The study protocol and assessments were
conducted in accordance with the Declaration of Helsinki
(2004) and the International Conference on Harmonisation
Guidelines for Good Clinical Practice (1996), and approved by
country-specific regulatory agencies. All study materials were
translated into local languages, and data obtained were trans-
lated back into English for analysis.
Study Population
Consecutive patients were enrolled during a routinely sched-
uled clinical consultation with their healthcare provider. Eligi-
ble patients were aged ≥18 years at baseline, with T1D or T2D
treated with insulin for >12months, who had given informed
consent to participate in the study. Exclusion criteria included
non-ambulatory status and illiteracy or other issues resulting in
an inability to complete a written questionnaire. Patients were
not paid for their participation in the study.
Assessments
The study comprised a two-part SAQ. Part 1 was a
cross-sectional assessment used to record baseline demo-
graphic and treatment information, as well as the history of
severe hypoglycaemia over the last 6 months and non-severe
hypoglycaemia over the previous 4weeks in the lead up to
baseline study entry. Part 2, completed 4weeks later, evaluated
the occurrence of both severe and non-severe hypoglycaemia
over the 4weeks following baseline study entry. To assist recall,
patients were provided with a diary, which was also used
to record hypoglycaemic events anonymously. If a patient
recorded more hypoglycaemic events using the patient diary
than the Part 2 SAQ, the patient diary value was used to calcu-
late prevalence of hypoglycaemia in the 4 weeks after baseline,
to compensate for potential underestimates attributable to
recall bias.
Study Objectives
The primary endpoint of the study was the percentage of
patients experiencing at least one hypoglycaemic event during
the 4-week follow-up period. Secondary endpoints included:
hypoglycaemia rates, HbA1c level at baseline, relationship
between HbA1c and hypoglycaemia, including proportion
of patients with HbA1c <7.0% (53mmol/l) and >9.0%
(75mmol/l) with or without hypoglycaemia, and relation-
ship between hypoglycaemia and factors such as age, fear
of hypoglycaemia, disease duration and duration of insulin
use. Although the study included both retrospective and
prospective collection periods, this report has focused on data
obtained in the prospective period, since it may be less prone
to recall bias.
Hypoglycaemia Classification
Categories of hypoglycaemia recorded in the questionnaire
and patient diary included non-severe hypoglycaemia (defined
as an event managed by the patient alone), severe hypogly-
caemia (defined, based on the American Diabetes Association
definition, as any hypoglycaemic event requiring assistance of
another person to administer carbohydrate, glucagon or other
resuscitative actions [14]) and nocturnal hypoglycaemia (any
event occurring between midnight and 06:00 hours). A com-
bined measure of any hypoglycaemia, based on the sum of all
individual hypoglycaemic events of any categories, was calcu-
lated based on diary and questionnaire entries.
Sample Size
Target sample size was based on the desired level of pre-
cision for estimating the percentage of patients experienc-
ing at least one hypoglycaemic event during the observation
period. Calculations of the percentage of patients experiencing
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Table 1. Characteristics of population.
Characteristic T1D (n= 8022) T2D (n= 19 563)
Sex: male/female, % 48/52 53/47
Mean age, years (s.d.; IQR) 42.1 (15.1; 28.0–50.0) 60.8 (10.9; 55.0–69.0)
Duration of diabetes, years (s.d.; IQR) 17.6 (12.0; 9.0–24.0) 13.7 (8.2; 8.0–20.0)
Duration of insulin use, years (s.d.; IQR) 17.0 (12.1; 8.0–24.0) 6.4 (5.6; 3.0–10.0)
HbA1c, mmol/mol (s.d.; IQR) 62.8 (16.2; 55.2–74.4) 64.2 (16.3; 51.9–73.8)
HbA1c*, % (s.d.; IQR) 7.9 (1.5; 7.2–9.0) 8.0 (1.5; 6.9–8.9)
Checks blood sugar levels, n (%)
Yes 7888 (98.6) 17,858 (91.6)
No 110 (1.4) 1635 (8.4)
Has experienced hypoglycaemia, n (%)
Yes 7759 (97.4) 15,167 (78.3)
No 159 (2.0) 3272 (16.9)
Not sure 49 (0.6) 940 (4.9)
IQR, interquartile range; s.d., standard deviation.
*Calculated, not measured.
a hypoglycaemic event and the 95% confidence interval (CI) for
various sample sizes indicated that the optimum CI precision
would be achieved with a sample size of 12 000. Assuming a
SAQ Part 2 responder rate of 37%, the total number of patients
to be screened was determined to be ∼32 000.
Statistical Analyses
All statistical tests were two-sided and regarded as exploratory,
with the criterion for statistical significance set at p< 0.05. No
adjustments were made for multiple comparisons.
For the primary endpoint, the percentage of patients experi-
encing any hypoglycaemia during the observation period was
calculated together with the 95% CI for this percentage. For
the secondary endpoints of severe or nocturnal hypoglycaemic
events, the number and proportion of patients having an event,
number of events, follow-up time (patient-years), estimated
hypoglycaemia rate with corresponding 95%CI, and number of
patients missing, was presented for the 4weeks after baseline.
Univariate negative binomial regression models, based on
the completer analysis set (patients who completed the Part
2 SAQ), stratified by country, specifying a log-transformed
exposure time offset term and adjusted for all variables in
the model, were used to examine the relationship between
hypoglycaemia and the following factors: age in years, gen-
der, HbA1c in mmol/mol and percentage, duration of diabetes
in years, duration of insulin therapy in years, type of insulin
therapy, frequency of blood glucose testing in average number
of checks per day, knowledge of hypoglycaemia (i.e. knowing
what hypoglycaemia is before reading the definition in the SAQ
introduction), fear of hypoglycaemia, study period (prospec-
tive/retrospective) and diabetes type. Given that the majority
of analyses were descriptive in nature, no imputation ofmissing
data was performed.
Results
Patient Characteristics
A total of 27 585 patients (T1D, n= 8022; T2D, n= 19 563)
completed Part 1. Of these, 25 505 patients (T1D, n= 7070;
T2D, n= 18 435) completed Part 2 and 23 627 patients (T1D,
n= 6822; T2D, n= 16 805) completed the patient diary.
Descriptive baseline characteristics of the global population
are shown in Table 1. A total of 51.2% of the study cohort were
male. Those with T1D were younger than those with T2D (age
42.1 years vs. 60.8 years, respectively), had a longer duration of
diabetes (17.6 years vs. 13.7 years, respectively) and, as insulin
use in patients with T1D starts at diagnosis, had therefore
been using insulin for a longer period than patients with T2D
(17.0 years vs. 6.4 years, respectively). Levels of glycaemic
control, in terms of HbA1c, were similar in patients with T1D
and T2D [7.9% (63mmol/l) vs. 8.0% (64mmol/l), respec-
tively]. In total, 44.6% of all patients defined hypoglycaemia by
using both symptoms and blood glucose measurements rather
than by symptoms alone [T1D, 49.1% (n= 3758); T2D, 42.3%
(n= 6231)].
Regional completion rates of the questionnaires and diaries
are shown in Table S1 (Supporting Information), with regional
baseline characteristics shown in Tables S2 and S3, Support-
ing Information, for T1D and T2D, respectively. HbA1c levels
were numerically higher in regions outside Europe and Canada
(Latin America, Middle East, Russia and SE Asia groups),
whereas the duration of diabetes and of insulin usewere numer-
ically higher in Northern Europe/Canada.
Reporting of Hypoglycaemia
In the 4weeks after baseline, 5886 patients with T1D (83.0%;
95% CI 82.1–83.9) and 8580 patients with T2D (46.5%; 95%
CI 45.8–47.2) reported experiencing at least one hypogly-
caemic event. Estimated annual rates of any hypoglycaemia in
the prospective period were 73.3 events/patient-year (95% CI
72.6–74.0) and 19.3 events/patient-year (95% CI 19.1–19.6) for
patients with T1D and T2D, respectively.
Nocturnal hypoglycaemiawas reported in 2768 patients with
T1D (40.6%; 95% CI 39.4–41.7), with an estimated rate of
11.3 events/patient-year (95% CI 11.0–11.6). A total of 2800
patients with T2D (15.9%; 95% CI 15.4–16.5) reported noctur-
nal hypoglycaemia, with a rate of 3.7 events/patient-year (95%
CI 3.6–3.8).
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Figure 1. Overall and nocturnal hypoglycaemia rates during the prospective period by geographic region. (A) Patients with type 1 diabetes. (B) Patients
with type 2 diabetes. PPY, per patient-year; SE, Southeast.
Overall, 1024 patients with T1D (14.4%; 95% CI 13.6–15.3)
and 1635 patients with T2D (8.9%; 95% CI 8.5–9.3)
reported a severe hypoglycaemic event. Annual rates of
severe hypoglycaemia based on the prospective period
were 4.9 events/patient-year (95% CI 4.7–5.1) and 2.5
events/patient-year (95%CI 2.4–2.5) for T1D and T2D, respec-
tively. The rates of hypoglycaemia requiring hospitalization
during the prospective period were 0.237 events/patient-year
(95% CI 0.198–0.283) for patients with T1D and 0.221 (95% CI
0.196–0.247) for patients with T2D. Rates of hypoglycaemia by
age group in the 4 weeks after baseline are shown in Table S5,
Supporting Information.
Regional Differences in Hypoglycaemia Rates
The proportions of patients with T1D experiencing hypo-
glycaemia were 86.7% (1558/1797) for Northern Europe
and Canada, 85.0% (2583/3052) for Eastern Europe, 87.4%
(373/427) for Latin America, 72.0% (718/997) for the Middle
East, 87.4% (533/611) for Russia, and 54.0% (121/224) for
SE Asia. The proportions of patients with T2D experiencing
hypoglycaemia were 43.6% (1460/3352) for Northern Europe
and Canada, 53.8% (3312/6218) for Eastern Europe, 43.8%
(644/1469) for Latin America, 39.1% (1149/2942) for the Mid-
dle East, 62.6% (454/726) for Russia, and 41.0% (1561/3811)
for SE Asia.
Overall and nocturnal hypoglycaemia rates are shown in
Figure 1, broken down by region and type of diabetes. Over-
all hypoglycaemia rates for patients with T1D were highest in
Northern Europe and Canada, and Latin America (91.6 and
93.9 events/patient-year, respectively) compared with rates of
∼70 events/patient-year for all other regions surveyed, with the
exception of SE Asia (17.5 events/patient-year). Latin Amer-
ica also had the highest rates of nocturnal hypoglycaemia in
patients with T1D (17.7 events/patient-year). Overall hypogly-
caemia rates in patients with T2D were consistent across most
participating regions, with the highest rates being in Eastern
Europe and Russia (23.7 and 28.1 events/patient-year, respec-
tively). Russia also had the highest rates of nocturnal hypogly-
caemia in patients with T2D (6.4 events/patient-year).
Severe hypoglycaemia rates by region are shown in Table S4,
Supporting Information. The highest rates for severe hypogly-
caemia in T1D were reported in Latin America and the Middle
East, whereas the highest rates for severe hypoglycaemia inT2D
were reported in Latin America and SE Asia.
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Figure 2. Relationship between estimated rates of any hypoglycaemia and (A) duration of insulin treatment and (B) duration of diabetes. Fully adjusted
negative binomial modelling of the associations between patient characteristics and incidence rate ratios for (C) any, (D) nocturnal or (E) severe
hypoglycaemia in the global trial population. Part A shows duration of insulin therapy for type 1 diabetes (T1D), lower quartile 7.0 years, median 15.0 years,
upper quartile 24.0 years; for type 2 diabetes (T2D), lower quartile 2.0 years, median 5.0 years, upper quartile 9.0 years. Part B shows duration of diabetes for
T1D, lower quartile 8.0 years, median 15.0 years, upper quartile 24.0 years; for T2D, lower quartile 8.0 years, median 12.0 years, upper quartile 18.0 years.
HbA1c, glycated haemoglobin; PPY, per patient-year.
Factors Associated with Hypoglycaemia
A numerical increase in hypoglycaemia rate was observed with
increased duration of diabetes and increased duration of insulin
therapy for both T1D and T2D (Figure 2).
Fully adjusted negative binomial modelling results for asso-
ciation between any, nocturnal or severe hypoglycaemia and
age, HbA1c, duration of diabetes, duration of insulin use, and
fear of hypoglycaemia (as indicated on a 10-point scale), are
shown in Figure 2C–E.
Older age was associated with a reduced risk of any hypo-
glycaemia in patients with T1D or T2D: rate ratio 0.99 (95%
CI 0.99; 0.99; p< 0.001). Duration of insulin therapy was asso-
ciated with overall, nocturnal and severe hypoglycaemia in
patients with T2D. Fear of hypoglycaemia was associated both
with any hypoglycaemia and nocturnal hypoglycaemia in T2D,
whereas severe hypoglycaemia was associated with greater fear
of hypoglycaemia in both T1D and T2D.
To elucidate further the association between HbA1c and
hypoglycaemia, the proportion of patients with any hypogly-
caemic event by HbA1c level is plotted for T1D and T2D in
Figure 3. HbA1c was not found to be a significant predictor of
hypoglycaemia.
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Figure 3. Percentage of patients reporting hypoglycaemia during the
prospective period, stratified by glycated haemoglobin (HbA1c) level for
patients with type 1 and type 2 diabetes.
Discussion
The present study examined hypoglycaemia prevalence and
rates in a large global cohort of insulin-treated patients with
diabetes, including many countries and several regions with
no previously published data. Patient-reported hypoglycaemia
in a global population occurred at a higher frequency than
previously reported, with marked variations across geographic
regions. Patients with T1D in Northern Europe/Canada and
Latin America reported the highest rates of any hypoglycaemia.
Regional differences in both overall and nocturnal hypogly-
caemia were also observed in patients with T2D, with the high-
est rates being reported in Russia and Eastern Europe and the
lowest rates in SE Asia and the Middle East. Differences were
also apparent in severe hypoglycaemia rates. Notably, Latin
America had the highest rates of severe hypoglycaemia for T1D
and T2D. Hypoglycaemia rates were only weakly associated
with HbA1c level for T1D and did not appear to be signifi-
cantly associated with HbA1c level in T2D. There was an asso-
ciation between increased rates of hypoglycaemia and duration
of insulin therapy in T2D.No other strong associations between
hypoglycaemia and the specified variables were evident in this
study.
Limitations of the HAT study include its observational
nature and short prospective duration; however, these charac-
teristics allowed a large patient pool from which meaningful
observations regarding the real-life rate and impact of hypo-
glycaemia could be made. Whilst the HAT study represents an
advance on previous studies in estimating the global prevalence
of hypoglycaemia, willingness to participate and local literacy
rates are likely to have affected the participant characteristics.
The simplicity of the questionnaires, although limiting the
amount of additional information available for subsequent
sub-analyses, may also have contributed to the high comple-
tion rate. The questionnaire did not record insulin regimen or
sulphonylurea use, both of which could contribute to regional
differences in the rate of hypoglycaemia. Patient diaries were
used in the prospective period in addition to the Part 2 SAQ to
reduce recall bias. Use of patient-reported data from the diaries
in addition to the SAQ Part 2 may have increased the reliability
of data on prevalence of hypoglycaemia but has the potential
to overestimate hypoglycaemia rates.
In the present study, as with previous self-reporting studies,
patients were permitted to record a hypoglycaemic episode by
either symptoms or blood glucose testing alone, or in combina-
tion. This approach represents both a strength and a limitation
of the study; it aided the capture of events in which patients
forgot or neglected to test blood glucose, did not know the
blood glucose concentration threshold for hypoglycaemia, or
were unable to test because of a lack of testing devices/materials,
but also introduced the potential for confounding because of
the subjective nature of the assessment. The lack of newly diag-
nosed/treated patients (<12months insulin use) in HAT could
affect the observed rates of hypoglycaemia; however, this group
is only a small proportion of the total population with T2DM
and is unlikely to have a significant effect on the mean values.
In addition, the hypoglycaemia event rates are typically lower
in this population [15].
We report higher estimated annual rates of hypoglycaemia
for both T1D and T2D than previously observed in other
studies (mainly randomized controlled trials) [16–19]. In the
Veterans Affairs Diabetes Trial, a randomized trial of intensive
glucose control in T2D which followed 1791 selected patients
for a median of 5.6 years, rates of any symptomatic hypogly-
caemic episode were 383–1333 per 100 patient years, whereas
rates of severe hypoglycaemia were 3–9 per 100 patient years
[16]. Results from the present observational study, which
included both patients with T1D and T2D who had been
using insulin for at least 1 year, and collected data both ret-
rospectively and prospectively, differ by at least one order of
magnitude from these data. Such marked differences are likely
to be attributable both to the controlled nature of randomized
trials and the exclusion of patients who experience recur-
rent severe hypoglycaemia or hypoglycaemia unawareness
(occasionally/never have symptoms associated with low blood
sugar measurement), are older, or have other concomitant
diseases, from participating in clinical trials [20]. Hypogly-
caemia rates reported from observational studies are somewhat
higher, with rates of 42.9 events/patient-year and 1.15 severe
events/patient-year for patients with T1D, compared with
16.37 events/patient-year and 0.35 severe events/patient-year
for patients with T2D in a recent population-based study
[20], whereas the monthly rates of hypoglycaemia were
somewhat higher in the DIALOG study, at 6.3/month (T1D)
and 1.6/month (T2D) [21]. The UK Hypoglycaemia Study,
which stratified subjects according to duration of insulin use,
reported mild hypoglycaemia rates of 10.2 events/patient-year
and severe hypoglycaemia rates of 0.7 events/patient-year in
patients with T2D using insulin for >5 years [22]. A recent
meta-analysis of 46 population-based studies of people with
T2D found a higher prevalence of mild/moderate hypogly-
caemia and severe hypoglycaemia in patients using insulin
(23 events/patient-year and one event/patient-year, respec-
tively) [23]. These rates are mostly lower than those seen in
the overall HAT study, but are broadly similar to the results
we report in the present Northern Europe/Canada cohort;
however, there are no other published data as a comparator for
most of the regions included in the HAT study. The duration
of diabetes reported in the present study was longer than in
the 9–12-month observational study carried out by the UK
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Hypoglycaemia Study group [22]. Considering the duration of
disease, HbA1c appeared to be relatively well controlled across
the large HAT study cohort. The lack of correlation between
HbA1c and hypoglycaemia for T2D in this studymay appear to
be counter-intuitive; however, it is important to keep in mind
that the nature of the study was non-interventional and hence
the findings might be a true representation of what happens in
clinical practice.
The high rates of hypoglycaemia in patients with T1D in
Northern Europe/Canada may partly be related to the dura-
tion of diabetes and duration of insulin use in this popula-
tion, which, possibly as a result of better prognosis, were con-
siderably higher than those for other regions (Table S2, Sup-
porting Information), but the high rate of hypoglycaemia in
T1D seen in Latin America compared with a region such as
Eastern Europe, which has similar baseline population charac-
teristics, may reflect regional differences in diabetes manage-
ment. Relatively low rates of hypoglycaemia among patients
with T1D observed in SE Asia could reflect the relatively
low average duration of diabetes (11.6 years) and high HbA1c
8.9% (74mmol/mol), but could also have a variety of other
causes, such as differences in self-monitoring, and should be
interpreted with caution because of the relatively low num-
ber of patients (n= 224). While the level of patient access to
self-monitoring of blood glucose equipment was not captured
in the present study, 53% of patients with T1D and 38% of those
with T2D in SEAsia increased blood glucosemonitoring after a
hypoglycaemic event, suggesting that access to self-monitoring
was fairly widespread; however, we cannot confirm the propor-
tion of patients with access to self-monitoring represented in
these figures [24]. When examining how regional differences
in hypoglycaemia in patients with T2D may relate to patient
characteristics, it appears that patients in Russia and Eastern
Europe were older, and had been receiving insulin therapy for
longer than patients in the SE Asia and Middle East cohorts
(longer disease duration and longer duration of insulin ther-
apy were associated with increased rates of hypoglycaemia in
the HAT study). Nevertheless, these regional differences, par-
ticularly when occurring between groups with similar base-
line characteristics, may imply lack of knowledge or awareness
of hypoglycaemia and indicate that there are opportunities to
optimize diabetes care further in those countries with higher
hypoglycaemia rates.Theweak association betweenHbA1c and
hypoglycaemia for T1D observed in the HAT study is in agree-
ment with a recent trend analysis conducted in a large (n> 35
000) patient cohort, which concluded that the association of
HbA1c with hypoglycaemia in T1D has decreased in recent
years [25], possibly because patients today are titrated to the
limit of hypoglycaemia. These findings suggest that the link
between HbA1c and hypoglycaemia may be more subtle than
previously anticipated, thereby supporting the call for tailored,
individualized treatment based on early response to treatment
adjustments [2]. The association of hypoglycaemia with dura-
tion of insulin therapy in patients with T2D may reflect the
progressive nature of this disease, which is accompanied by a
need formore intensive insulin therapy and impaired hormonal
counter-regulation [26,27]. The association of fear of hypogly-
caemia with any and nocturnal hypoglycaemia in patients with
T2D probably arises because patients who experience hypogly-
caemia more frequently report greater fear of hypoglycaemia
as a result. This association may be particularly true of severe
hypoglycaemia, which was associated with greater fear of hypo-
glycaemia in both patients with T1D and those with T2D. It
is envisaged that these observations, together with those pre-
viously reported, will aid clinicians in better tailoring insulin
treatment for patients with diabetes, particularly in regions
where such data were previously unavailable.
Further studies and analyses are required to investigate the
reasons for the differences in hypoglycaemia rates between
the global regions. The lack of any strong association between
hypoglycaemia and conventional predictive factors, generally
and across regions, in the present study requires exploration of
other domains such as ethnic, cultural and healthcare organiza-
tional aspects so as to reduce this very complex and important
clinical problem.
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